2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Unknown
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
256
Thoracic
101
Breast
88
CNS
83
Head & Neck
72
Sarcoma
56
Gynecologic
46
Genitourinary
39
Dermatologic
28
Endocrine
12
Tumor-Agnostic
9
Other solid neoplasm
5
Other
2
NET
2
Other neoplasm
1
Other hematologic neoplasm
1
Lymphoid
1
Classical hematology
1
Conditions
Neuroendocrine Tumors
2
Neoplasm Metastasis
1
Interventions
lutetium Lu 177 dotatate
48
Everolimus
40
Magnetic Resonance Spectroscopy
21
lanreotide
17
Temozolomide
17
gallium Ga 68 dotatate
15
Octreotide
15
pembrolizumab
13
Nivolumab
13
surufatinib
12
Capecitabine
12
cabozantinib
11
177Lu-octreotide, DOTA(0)-Tyr(3)-
11
Sunitinib
10
pasireotide
9
Specimen Handling
9
Positron Emission Tomography Computed Tomography
9
Lutetium-177
9
3-Iodobenzylguanidine
9
Ga(III)-DOTATOC
8
Carboplatin
8
telotristat ethyl
6
copper dotatate CU-64
6
amino-acid, glucose, and electrolyte solution
6
Somatostatin
6
Ipilimumab
6
Fluorodeoxyglucose F18
6
Etoposide
6
Cisplatin
6
90Y-octreotide, DOTA-Tyr(3)-
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Surgical Procedures, Operative
×
NET
×
Clear all
NCT03012789
2024-04-30
NETest_Sx
Wren Laboratories LLC
Phase NA
Active not recruiting
40 enrolled
NCT04066322
2019-09-24
RMPanNET
Fudan University
Unknown
180 enrolled